Open AccessMeasurement of Mucosal Biomarkers in a Phase 1 Trial of Intravaginal 3% StarPharma LTD 7013 Gel (VivaGel) to Assess Expanded Safety
Author(s) -
AnnaBarbara Moscicki,
Rupert Kaul,
Yifei Ma,
Mark E. Scott,
Ibrahim I. Daud,
Elizabeth A. Bukusi,
Stephen Shiboski,
Anu Rebbapragada,
Sanja Huibner,
Craig R. Cohen
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31823f2aeb
Subject(s) - medicine
The aim of this study was to examine the effect of the 3% StarPharma LTD 7013 gel (VivaGel) on mucosal immune markers hypothesized to be associated with HIV-1 acquisition.